The Catalyst

Most Recent Posts

07.14.11 | By Kate Connors

Recently Bob Cobuzzi, Vice President of Corporate Development for Endo Pharmaceuticals, sat down in front of a camera for a few minutes to discuss the challenges faced by emerging American biopharmaceutical companies that are trying to reach markets outside the U.S.

07.14.11 | By Kate Connors

When discussing progress associated with medical innovation, we like to mention both life-saving and life-enhancing medicines. Why? Because so many debilitating chronic conditions may not be life-threatening, but the patients who live with them still deserve the best that healthcare has to offer.


With the new Battelle report focusing on how biopharmaceutical innovation helps to fuel the economy, I wanted to share a local view from Iowa. Tom Swegle is the Vice Chairman of the Iowa Biotechnology Association and he recently published a great oped in the Des Moines Register.

07.13.11 | By Kate Connors

Monday, we discussed how policies that undercut the biopharmaceutical research sector could lead to huge job losses, with an annual reduction in sector revenue of $20 billion potentially leading to as many as 260,000 lost jobs.

07.12.11 | By Kate Connors

An article in today's Washington Post discusses how generic drugs can benefit America's overall healthcare system. In fact, nearly 80 percent of all prescriptions written in the U.S. are for generics, according to IMS Health.

07.11.11 | By Kate Connors

It's no secret that the biopharmaceutical sector provides jobs - and a wide range of jobs, at that. We're not just researchers in lab coats. In terms of jobs we support, we're also the drivers of trucks that help medicines reach pharmacies, the construction workers and technicians who help construct the facilities and equipment necessary for manufacture of medicines, and more. Ultimately, it's an intricate web of workers that all play a role in the important work that we do.


A recent editorial in the New York Times delved into some overarching issues around coverage of cancer medicine. While the paper raises some interesting questions, it unfortunately missed a few key considerations in trying to come up with answers.


At PhRMA and our member companies, we're proud and excited by how the nearly 900 medicines now being developed to fight cancer may help patients struggling with the disease.

07.07.11 | By Kate Connors

This week, I had the chance to speak with Dr. Marc S. Ernstoff from Dartmouth College's Dartmouth-Hitchcock Medical Center. Dr. Ernstoff, a leading oncologist and melanoma researcher, took the time to explain to me some of the latest advances in the field.

Tell us how you became involved in melanoma research?

07.06.11 | By Kate Connors

Yesterday, The Hill's Congress Blog ran a column by Nicole Boice, founder and CEO of the Children's Rare Disease Network, about how the Prescription Drug User Fee Act (PDUFA) has helped to bring orphan medicines to pediatric patients.


PhRMA recently released its report on the nearly 300 new medicines now being developed to help fight skin diseases. The report looks at new medicines now in late-stage clinical trials or currently before the FDA for final approval for patient use.

07.05.11 | By Kate Connors

PhRMA recently released its Medicines in Development for Skin Diseases report, which found 74 medicines in development for skin cancers.

06.29.11 | By Kate Connors

Yesterday, representatives from emerging companies spoke at the BIO International Convention about the work they are doing in the field of personalized medicine.


A piece on the increasing, world-wide problem of diabetes in the Washington Post this past weekend should give us all pause.

06.28.11 | By Kate Connors

At the end of the day yesterday, R&D experts from an assortment of biopharmaceutical research companies as well as venture capital came together to discuss what the future of the sector will look like from an innovation standpoint.